Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of o3mega+Joy in the Treatment of Social Phobia
NCT00485615Phase 2Completed
- Sponsor
- START Clinic for Mood and Anxiety Disorders
- Start
- Oct 2008
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eicosapentaenoic acid in Social Anxiety Disorder (SAD), sponsored by START Clinic for Mood and Anxiety Disorders. Primary endpoint: Changes in intensity of the vasodilatory response to 10 mM topical m-N at 16 weeks. Started Oct 2008; status: completed.
02
Drugs
eicosapentaenoic acid
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT00485615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00485615.